Cardiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Early Clinical Development, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Eur J Heart Fail. 2022 Dec;24(12):2251-2260. doi: 10.1002/ejhf.2709. Epub 2022 Oct 20.
Epicardial adipose tissue (EAT) may play a role in the pathophysiology of heart failure with preserved ejection fraction (HFpEF). We investigated associations of EAT with proteomics, coronary flow reserve (CFR), cardiac structure and function, and quality of life (QoL) in the prospective multinational PROMIS-HFpEF cohort.
Epicardial adipose tissue was measured by echocardiography in 182 patients and defined as increased if ≥9 mm. Proteins were measured using high-throughput proximity extension assays. Microvascular dysfunction was evaluated with Doppler-based CFR, cardiac structural and functional indices with echocardiography and QoL by Kansas City Cardiomyopathy Questionnaire (KCCQ). Patients with increased EAT (n = 54; 30%) had higher body mass index (32 [28-40] vs. 27 [23-30] kg/m ; p < 0.001), lower N-terminal pro-B-type natriuretic peptide (466 [193-1133] vs. 1120 [494-1990] pg/ml; p < 0.001), smaller indexed left ventricular (LV) end-diastolic and left atrial (LA) volumes and tendency to lower KCCQ score. Non-indexed LV/LA volumes did not differ between groups. When adjusted for body mass index, EAT remained associated with LV septal wall thickness (coefficient 1.02, 95% confidence interval [CI] 1.00-1.04; p = 0.018) and mitral E wave deceleration time (coefficient 1.03, 95% CI 1.01-1.05; p = 0.005). Increased EAT was associated with proteomic markers of adipose biology and inflammation, insulin resistance, endothelial dysfunction, and dyslipidaemia but not significantly with CFR.
Increased EAT was associated with cardiac structural alterations and proteins expressing adiposity, inflammation, lower insulin sensitivity and endothelial dysfunction related to HFpEF pathology, probably driven by general obesity. Potential local mechanical or paracrine effects mediated by EAT remain to be elucidated.
心外膜脂肪组织(EAT)可能在射血分数保留的心力衰竭(HFpEF)的病理生理学中发挥作用。我们在前瞻性多国 PROMIS-HFpEF 队列中研究了 EAT 与蛋白质组学、冠状血流储备(CFR)、心脏结构和功能以及生活质量(QoL)的相关性。
通过超声心动图测量 182 例患者的心外膜脂肪组织,如果≥9mm 则定义为增加。使用高通量邻近延伸测定法测量蛋白质。用基于多普勒的 CFR 评估微血管功能障碍,用超声心动图评估心脏结构和功能指标,用堪萨斯城心肌病问卷(KCCQ)评估 QoL。EAT 增加的患者(n=54;30%)具有更高的体重指数(32[28-40] vs. 27[23-30]kg/m 2 ;p<0.001),更低的 N 末端脑利钠肽前体(466[193-1133] vs. 1120[494-1990]pg/ml;p<0.001),更小的左心室(LV)舒张末期和左心房(LA)指数容积,以及 KCCQ 评分降低的趋势。两组间非指数化的 LV/LA 容积无差异。当按体重指数调整时,EAT 仍与 LV 间隔壁厚度相关(系数 1.02,95%置信区间[CI]1.00-1.04;p=0.018)和二尖瓣 E 波减速时间相关(系数 1.03,95%CI 1.01-1.05;p=0.005)。EAT 增加与脂肪生物学和炎症、胰岛素抵抗、内皮功能障碍和血脂异常的蛋白质标志物相关,但与 CFR 无显著相关性。
EAT 增加与 HFpEF 病理相关的心脏结构改变和表达肥胖、炎症、胰岛素敏感性降低和内皮功能障碍的蛋白质有关,可能由一般肥胖驱动。EAT 介导的潜在局部机械或旁分泌作用仍有待阐明。